Article citationsMore>>
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lassig, B., Salanti, G. and Davis, J.M. (2013) Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. Lancet, 382, 951-962.
http://dx.doi.org/10.1016/S0140-6736(13)60733-3
has been cited by the following article:
-
TITLE:
Case Reports: Treatment-Resistant Schizophrenia with Severe Type 2 Diabetes Mellitus Treated with Clozapine
AUTHORS:
Junji Gon, Shinji Sakamoto, Manabu Takaki
KEYWORDS:
Clozapine, Treatment-Resistant Schizophrenia, Type 2 Diabetes Mellitus, Brief Assessment of Cognition in Schizophrenia Japanese Version
JOURNAL NAME:
Open Journal of Psychiatry,
Vol.6 No.1,
January
11,
2016
ABSTRACT: Objective: Clozapine is
regarded as the most effective drug for treatment of schizophrenia but has
complex adverse effects associated with hyperglycemia and diabetes mellitus.
Method: We report that clozapine was very effective to treat positive,
negative, and cognitive symptoms and well tolerated to a treatment-resistant
schizophrenia patient with severe type 2 diabetes mellitus (DM) under cautious blood-sugar
monitoring. Results: Clozapine itself and discontinuation of other psychotropic
and anticholinergic agents after switching may improve cognitive function and
adherence to the treatment regimens for schizophrenia and DM. Conclusion:
Clozapine can be administered to treatment-resistant schizophrenia patients
even with severe DM with caution.
Related Articles:
-
Rafael Bolaños-Díaz, Héctor Velarde-Criado, Erik Cóndor-Mori
-
Masoud Behzadifar, Hamidreza Dehghan, Korush Saki, Meysam Behzadifar, Abouzar Keshavarzi, Maryam Saran, Ali Akbari Sari
-
Sensuke Konno, Bobby Alexander, Drew Freilich, Muhammad Choudhury
-
Keiko Ikemoto
-
Alexa Bremmer